DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ULORIC

Summary for Tradename: ULORIC

Patents:4
Applicants:1
NDAs:1
Suppliers: see list3
drug
patent expirations by year for
 ULORIC

Pharmacology for Tradename: ULORIC

Clinical Trials for: ULORIC

The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study
Status: Terminated Condition: Blood Pressure; Gout

Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
Status: Completed Condition: Chronic Kidney Disease; Diabetes

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment
Status: Completed Condition: Renal Impairment

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.
Status: Completed Condition: Gout

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout
Status: Recruiting Condition: Gout

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia
Status: Completed Condition: Gout; Hyperuricemia

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment
Status: Recruiting Condition: Gout; Moderate Renal Impairment

Febuxostat Versus Allopurinol Control Trial in Subjects With Gout
Status: Completed Condition: Gout

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010
Status: Completed Condition: Gout

Efficacy and Safety of Oral Febuxostat in Participants With Gout
Status: Completed Condition: Gout

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856Feb 13, 2009RXNo<disabled><disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856Feb 13, 2009RXNo5,614,520<disabled>YY<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856Feb 13, 2009RXNo6,225,474<disabled>Y<disabled>
Takeda Pharms Usa
ULORIC
febuxostat
TABLET;ORAL021856Feb 13, 2009RXNo7,361,676<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ULORIC

Drugname Dosage Strength RLD Submissiondate
febuxostatTablets40 mg and 80 mgUloric2/13/2013

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc